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Background: to aid decision making for pneumococcal conjugate vaccine 
(pCV) use in infant national immunization programs, we summarized the 
indirect effects of pCV on clinical outcomes among nontargeted age groups.
Methods: We systematically reviewed the english literature on infant pCV 
dosing schedules published from 1994 to 2010 (with ad hoc addition of 
2011 articles) for outcomes on children >5 years of age and adults includ-
ing vaccine-type nasopharyngeal carriage (Vt-np), vaccine-type invasive 
pneumococcal disease (Vt-IpD) and syndromic pneumonia.
Results: Of 12,980 citations reviewed, we identified 21 Vt-IpD, 6 Vt-np and 9 
pneumonia studies. Of these 36, 21 (58%) included 3 primary doses plus pCV 
or pneumococcal polysaccharide vaccine (ppV23) booster schedule (3+1 or 
3+ppV23), 5 (14%) 3+0, 9 (25%) 2+1 and 1 (3%) 2+0. most (95%) were pCV7 
studies. Among observational Vt-IpD studies, all schedules (2+1, 3+0 and 3+1) 
demonstrated reductions in incidence among young adult groups. Among syn-
dromic pneumonia observational studies (2+1, 3+0 and 3+1), only 3+1 schedules 
showed significant indirect impact. Of 2 Vt-np controlled trials (3+0 and 3+1) 
and 3 Vt-np observational studies (2+1, 3+1 and 3+ppV23), 3+1 and 3+ppV23 
schedules showed significant indirect effect. the 1 study to directly compare 
between schedules was a Vt-np study (2+0 vs. 2+1), which found no indirect 
effect on older siblings and parents of vaccinated children with either schedule.
Conclusions: Indirect benefit of a 3+1 infant pCV dosing schedule has been 
demonstrated for Vt-IpD, Vt-np and syndromic pneumonia; 2+1 and 3+0 
schedules have demonstrated indirect effect only for Vt-IpD. the choice of 
optimal infant pCV schedule is limited by data paucity on indirect effects, 
especially a lack of head-to-head studies and studies of pCV10 and pCV13.
Key Words: pneumococcal conjugate vaccine, nasopharyngeal carriage, 
pneumonia, pneumococcal disease, indirect effects
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Pneumococcal conjugate vaccines (pCV) have been available for use in infants for over a decade and have played an integral role 
in the prevention of disease caused by Streptococcus pneumoniae in 
children in higher income settings.1 However, until recently, avail-
ability of pCV for children living in lower income countries has 
been limited. this situation is now changing. In 2011, 18 GAVI-
eligible countries were approved to introduce pCV; an additional 
19 have been approved.2 As the feasibility of introducing pCV into 
childhood immunization programs has grown, the need to under-
stand the number and the timing of doses, which will maximize 
both direct and indirect effects, has become a key question.
much of the evidence regarding pCV impact has focused on 
young children targeted to receive vaccine using 2 primary doses 
plus a booster (2+1) or 3 primary doses with or without a booster 
(3+0 or 3+1).3–6 Clinical trials and observational studies have dem-
onstrated a significant direct impact of pCV on both vaccine-type 
invasive pneumococcal disease (Vt-IpD) and pneumococcal and 
syndromic pneumonia among children <5 years of age.3,6 Reduc-
tions in nasopharyngeal (np) carriage of vaccine-type pneumo-
cocci (Vt-np), a necessary precursor to clinical disease, have also 
been demonstrated among young children receiving the vaccine.4 
Because pneumococci are transmitted through respiratory secre-
tions, reductions in np carriage of pneumococci are a key factor 
toward indirect effects of vaccine introduction and the establish-
ment of “herd” protection. through herd protection, infant immuni-
zation indirectly protects groups not targeted to receive the vaccine 
by reducing the circulation of vaccine-type bacteria. prevention of 
disease among adults through herd protection has been shown to 
be an important benefit and a powerful driver of the cost effective-
ness of a pCV program in high-income settings.7 Whether different 
pCV dosing schedules may translate into noticeable differences in 
herd effects is unknown. Here, we present a systematic review of 
the literature summarizing the evidence on the indirect effects of 
pCV dosing schedules on Vt-IpD, Vt-np-carriage and syndromic 
pneumonia among groups not targeted to receive the vaccine.
MATERIALS AND METHODS
Literature Search
this analysis is part of a larger project describing the impact 
of pCV dosing schedules on IpD, immunogenicity, nasopharyngeal 
carriage, pneumonia and indirect effects.3–6 Details on the literature 
search terms and methods used in this systematic review are described 
elsewhere (see methods Appendix8). In brief, a systematic literature 
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review was performed to collect all available english language data 
published from January 1994 to September 2010 (supplemented post 
hoc with studies from 2011) on the effect of various pCV vaccination 
schedules among immunized children on immunogenicity, np colo-
nization, invasive pneumococcal disease, pneumonia and on indirect 
effects among unvaccinated populations. Articles published in 14 data-
bases, from ad hoc unpublished sources and abstracts from meetings 
of the International Symposium on pneumococci and pneumococcal 
Disease (1998–2010) and the Interscience Conference on Antimicro-
bial Agents and Chemotherapeutics (1994–2010), were searched. We 
included all randomized controlled clinical trials (RCts), nonrand-
omized trials, surveillance database analyses and observational stud-
ies of any pCV schedule on 1 or more outcomes of interest. Studies 
were included for abstraction if pneumococcal polysaccharide vaccine 
(ppV23) was used as a booster dose, but not as a primary dose. titles 
and abstracts were reviewed twice and those with relevant content on 1 
of the 5 outcomes (immunogenicity, carriage, invasive disease, pneu-
monia and indirect effects) underwent full review using a standardized 
data collection instrument. We did not search non-english language 
literature because of the low likelihood they would have the relevant 
data for this project. Details on the search methods are provided in the 
methods Appendix.8
Data Abstraction
Citations recovered through the literature search went 
through several stages of independent review to determine their eli-
gibility, as described elsewhere.8 Citations meeting inclusion criteria 
were categorized on an outcome specific basis into “study families,” 
where each family included abstracts or publications generated from 
a single protocol, population, surveillance system or other data col-
lection system relevant to that outcome. Investigators identified the 
primary data from the individual studies making up each study fam-
ily for inclusion in the analysis. the primary data were selected as 
the most current and complete data available for that study family. 
In some cases, these data were drawn from >1 publication within a 
family. We also defined “study arms” as a group of children distin-
guished by immunization schedule or pCV product.
We abstracted core information on the following: number of 
children in a “study arm”; pCV manufacturer, valency and conju-
gate protein; co-administered vaccines; country; age at each dose 
and date of study and publication. to assess indirect effects, we 
abstracted additional data from studies of the effects of pCV in 
unimmunized populations on Vt-IpD, Vt-np carriage and syn-
dromic pneumonia and included information on study design, case 
definitions and trends in the outcome of interest.
Inclusion and Exclusion Criteria
We included the data published during or after 1994 from 
clinical trials, surveillance database analyses and observational 
studies of pCV schedules on Vt-IpD, Vt-np carriage and syn-
dromic pneumonia. We included all licensed and unlicensed pCV 
products (denoted as pCV with a number indicating the valency, 
eg, pCV7). We excluded studies with vaccination series beginning 
after 12 months of life as well as the observational studies that only 
reported data before or after pCV introduction but not for both peri-
ods. unless ≥50% vaccination coverage was documented, the obser-
vational studies were also excluded if vaccination was only available 
through a private sector or only recommended for high-risk groups. 
Studies that only provided incidence rates during the year of vaccine 
introduction, or did not specify a time period, were excluded.
For IpD, we focused the analysis on the indirect effects 
among adults by including studies that reported data on specific 
age groups between 18 and 64 years (eg, 18–35 and 36–64 years), 
and those that were inclusive of age groups ≥65 or <18 years 
(eg, the “general population”). Studies that only reported data on 
age groups <18 or ≥65 years were excluded.
Pneumococcal Vaccine Dosing Schedules
We included pCV schedules with 2 or 3 primary doses with-
out a booster dose (2+0 and 3+0) and with a booster dose (2+1 and 
3+1). Schedules with either pCV or ppV23 boosters were included 
(2+ppV23 and 3+ppV23).
Data Analysis
Because the included studies used a variety of designs and 
methods, we were unable to perform a formal meta-analysis. thus, 
we summarized the data across studies in descriptive analyses to pro-
vide an overview of the amount and variability of data by outcome 
and schedule. For Vt-np carriage, each study was divided into arms, 
defined as a unique combination of vaccine schedule, age at np speci-
men collection and vaccine product used. Studies could have multiple 
arms. Vaccine-type pneumococci were defined as each study defined 
them, based on the product used. For carriage, no  studies included 
serotype 19A in Vt and 1 included serotype 6A in Vt.9 For IpD, 
no studies included serotypes 19A or 6A in Vt. We defined Vt-np 
carriage prevalence as the percentage of those sampled who carried 
Vt pneumococci, except in 2 studies that only reported the percent-
age of pneumococcal isolates found that were Vt.9,10 the syndromic 
pneumonia endpoint included clinical pneumonia, radiologically con-
firmed pneumonia and pneumococcal (eg, bacteremic) pneumonia.
For observational studies reporting Vt-IpD incidence over 
time, we calculated percent reduction by defining baseline incidence as 
the mean of all data points reported prior to introduction. When annual 
data on post introduction incidence were available, we calculated per-
cent reduction from baseline using the data point given for each year 
reported. In cases where only the average post introduction incidence 
rate over a period was provided, we calculated percent reduction from 
baseline to the reported rate and assigned it to the median year of the 
date range provided. When possible, incidence rates during the year 
of introduction were excluded from these calculations. percent reduc-
tion reported by the study was only used if no incidence rates were 
provided. therefore, the percent reduction over time presented in this 
review may not always be identical to that reported by the study.
We used microsoft Access 2003 and 2007 (microsoft Cor-
poration, Redmond, WA) for data abstraction and SAS 9.2 and 9.3 
(SAS Institute Inc., Cary, nC) to perform all analyses.
RESULTS
Of 12,980 citations reviewed, 36 studies (38 citations) met 
inclusion criteria for pCV indirect effects; of these, 21 were Vt-
IpD studies,11–31 9 were pneumonia syndrome studies11,32–39 and 6 
were Vt-np carriage studies9,10,40–45 (Fig. 1). Among the 36 studies, 
all were published in 2003 or later, and 28 (78%) were from europe 
or north America (table 1). Almost all (95%) studies evaluated 
pCV7; none evaluated pCV10 or pCV13.
Nasopharyngeal Carriage
this review identified 6 studies that evaluated the indirect 
impact of pCV on Vt-np carriage. All but 1 study were from north 
America, europe or Australia. Five studies  (83%) evaluated pCV7, 
including one with a ppV23 booster dose; 1 study (17%) evaluated 
pCV9. three studies (50%) evaluated the impact of pCV on Vt-np 
carriage in indigenous populations.
two studies (3 citations) among nonhigh-risk popula-
tions evaluated the indirect effects of either a 2+0 or 2+1 sched-
ule (table 2) on Vt-np carriage.41,44,45 One individual RCt in the 
netherlands found no Vt-np carriage indirect effect of pCV7 
given in 2+0 and 2+1 dosing schedules among parents and siblings 
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of vaccinated and unvaccinated children.44,45 One pre/postvaccine 
introduction observational study in the united Kingdom using a 2+1 
schedule with catch-up through 2 years of age found a nonsignifi-
cant reduction in Vt-np carriage 2–3 years after pCV7 introduction 
among children and adults ≥5 years of age (table 2).41 there were 
no studies that evaluated 2+0 or 2+1 schedules in high-risk popu-
lations, such as indigenous and immunocompromised populations.
One study evaluated a 3+0 (table 2) schedule on Vt-np 
carriage. this individual RCt found no effect on Vt-np carriage 
among unvaccinated younger siblings of children vaccinated with 
pCV9 or placebo in the Gambia.40 there was 1 RCt and 2 obser-
vational studies that evaluated a 3+1 or 3+ppV23 schedule in high-
risk populations; no studies evaluated a 3+0 schedule in high-risk 
populations (table 2). the observational carriage study in Australia 
among Aboriginals with 3+ppV23 found a significant indirect 
reduction of Vt-carriage among older children, but no difference 
among adults.10 A cluster-randomized, placebo-controlled trial 
evaluated Vt-carriage indirect effects among the navajo nation and 
White mountain Apache people.9,43 During the trial, Vt-carriage 
was reduced among household contacts (older and younger siblings) 
of pCV7 vaccinees, but reached statistical significance only for day-
care-attending contacts.9 However, at 3–15 months after completion 
of the trial, significant reductions were seen in Vt-carriage among 
unvaccinated children <5 years of age and adults living in communi-
ties randomized to pCV7 compared with placebo.43 Another obser-
vational study demonstrated a highly significant trend in reduction 
of Vt-carriage prevalence among Alaskan native adults in the 
4 years following the introduction of pCV7 with a 3+1 schedule.42
Invasive Pneumococcal Disease
We identified 21 studies documenting the impact of pCV 
introduction on incidence of Vt-IpD among adult age groups, 
FIGURE 1. Flow chart of included citations.
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TABLE 1. Summary of Characteristics from Included Studies
Number of Primary Studies
Variable Carriage (n = 6) IPD (n = 21) Pneumonia (n = 9)
Study publication date
  1994–1998 0 0 0
  1999–2002 0 0 0
  2003–2006 2 (33%) 0 1 (11%)
  2007–present 4 (67%) 21 (100%) 8 (89%)
Dosing schedule*
  2 + 0 1 (17%) 0 0
  2 + 1 2 (33%) 6 (29%) 1 (11%)
  3 + 0 1 (17%) 2 (10%) 2 (22%)
  3 + 1† 3 (50%) 14 (67%) 6 (67%)
United Nations Region
  Africa 1 (17%) 0 1 (11%)
  Asia 0 0 1 (11%)
  Oceania 1 (17%) 3 (14 %) 1 (11%)
  Europe 2 (33%) 9 (43%) 2 (22%)
  Latin America/Caribbean 0 0 0
  North America 2 (33%) 9 (43%) 4 (44%)
Population
  General 3 (50%) 17 (81%) 9 (100%)
  Indigenous 3 (50%) 4 (19%) 0
  HIV-infected 0 2 (10%) 0
*When not stated in the manuscript, dosing schedule was assigned according to national immunization program recom-
mendations.
†3 + 1 schedule includes 3 primary doses plus a PCV or PPV23 booster dose.
TABLE 2. Summary of Vaccine-Type Nasopharyngeal Carriage Studies Evaluating Indirect Effects
Country Reference Study Design Product
Dosing  
Schedule  
for PCV
Indirect Groups  
Evaluated Detailed Findings
2 + 0 schedules
  Netherlands Van Gils 
et al.44
Individual RCT 
compared to 
no vaccine
PCV7 
(Wyeth)
2 and 4 months Parents of  
vaccinated  
and control  
children
At vaccinated or control child’s age 12 months:
VT carriage: 8% in vaccine vs. 10% in control 
groups
 RR (95% CI) 0.86 (0.52–1.42)
At vaccinated or control child’s age 24 months:
VT carriage: 5% in vaccine vs. 8% in control 
groups
 RR (95% CI) 0.61 (0.33–1.12)
Van Gils 
et al.45
Individual RCT 
compared to 
no vaccine
PCV7 
(Wyeth)
2 and 4 months Siblings of  
vaccinated  
and control  
children
At vaccinated or control child’s age 12 months:
VT carriage: 24% in vaccine vs. 29% in control 
groups, not significant
2 + 1 schedules
  Netherlands Van Gils 
et al.44
Individual RCT 
compared to 
no vaccine
PCV7 
(Wyeth)
2, 4 and  
11 months
Parents of  
vaccinated  
and control  
children
VT-carriage prevalence
At vaccinated or control child’s age 12 months:
9% in vaccine vs. 10% in control groups
 Relative Risk (95% CI) 0.93 (0.57–1.52)
At vaccinated or control child’s age 24 months:
6% in vaccine vs. 8% in control groups
 Relative Risk (95% CI) 0.66 (0.37–1.19)
Van Gils 
et al.45
Individual RCT 
compared to 
no vaccine
PCV7 
(Wyeth)
2, 4 and  
11 months
Siblings of  
vaccinated  
and control  
children
VT-carriage prevalence
At vaccinated or control child’s age 12 months:
25% in vaccine vs. 29% in control groups, not 
significant
  United  
Kingdom
Flasche 
et al.41
Pre/postvaccine 
introduction 
observational 
study
PCV7 
(Wyeth)
2, 4 and  
13 months  
with catch-up  
to 2 years of age
Family members  
of children  
<5 years at  
primary care  
clinics:
5–20 year olds
>20 year olds
Vaccine introduction: September 2006
VT carriage prevalence
Among 5–20 year olds:
2001/2: 9.9% (7.3–13.3%)
2008/9: 0% (0–6.4%)
Among >20 year olds:
2001/2: 4.1% (3.0–5.5%)
2008/9: 2.3% (0–5.3%)
VT carriage reduction not significant in ≥5 year 
olds, not broken down between 5–20 and >20 
year olds
(Continued)
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Country Reference Study Design Product
Dosing  
Schedule  
for PCV
Indirect Groups 
Evaluated Detailed Findings
3 + 0 schedules
  The Gambia Cheung 
et al.40
Individually 
randomized, 
placebo- 
controlled 
clinical trial
PCV9 
(Wyeth)
3 doses starting 
at 6–51 weeks 
(median age at 
doses: 75, 122  
and 169 days)
Cross-section of 
younger siblings 
of children who 
received PCV9 or 
placebo
VT carriage prevalence:
At younger siblings average age of 3 months:
35.3% PCV9 vs. 37.1% placebo
Risk Ratio (95% CI): 0.95 (0.78–1.16)
3 + 1 schedules
  United  
States
O’Brien 
et al.9
Cluster-
randomized, 
placebo- 
controlled trial
PCV7 
(Wyeth)
2, 4, 6 and  
12–15 months
Navajo Nation and 
White Mountain 
Apache children 
and infants who 
were household 
contacts of  
vaccine or  
placebo-recipients
Percent of pneumococcal isolates that were 
VT+6A
Among household children
At vaccinee’s age of 7 months:
40.5% PCV7 vs. 45.3% placebo
Odds ratio (95% CI): 0.94 (0.66–1.34)
Odds ratio (95% CI) for those in daycare: 0.30 
(0.12–0.71)
Odds ratio (95% CI) for those not in daycare: 
1.78 (1.43–2.22)
At vaccinee’s age of 12 months:
41.4% PCV7 vs. 40% placebo
Odds ratio (95% CI): 1.63 (0.85–3.14)
Odds ratio (95% CI) for those in daycare: 0.46 
(0.13–1.62)
Odds ratio (95% CI) for those not in daycare: 
1.79 (0.99–3.24)
At vaccinee’s age of 15 months:
39.0% PCV7 vs. 50.0% placebo
Odds ratio (95% CI): 1.06 (0.84–1.34)
Odds ratio (95% CI) for those in daycare: 0.25 
(0.15–0.43)
Odds ratio (95% CI) for those not in daycare: 
1.31 (1.04–1.65)
Among household infants:
33.6% PCV7 vs. 47.8% placebo
Odds ratio (95% CI): 0.48 (0.32–1.05)
Odds ratio (95% CI) for those in household  
with PCV7-vaccinated member: 0.47 
(0.21–1.05)
Odds ratio (95% CI) for those in household 
without a PCV7-vaccinated member: 0.58 
(0.32–1.01)
Millar 
et al.43
Cluster-
randomized, 
placebo- 
controlled  
trial
PCV7 
(Wyeth)
2, 4, 6 and  
12–15 months
Navajo Nation  
and White  
Mountain Apache, 
unvaccinated  
children and  
adults who were 
household contacts 
of vaccine or 
placebo-recipients; 
3–15 months  
after completion  
of the trial
VT carriage prevalence
Among unvaccinated children <5 years:
12.0% PCV7 vs. 19% placebo
Odds ratio (95% CI) 0.57 (0.26–0.98)
Among unvaccinated children 5–17 years:
7.5% PCV7 vs. 8.0% placebo
Odds ratio (95% CI) 0.84 (0.56–1.29)
Among unvaccinated adults ≥18 years:
2.4% PCV7 vs. 4.1% placebo
Odds ratio (95% CI) 0.57 (0.33–0.99)
  United States Hammitt 
et al.42
Pre/postvaccine 
introduction 
observational 
study
PCV7 
(Wyeth)
2, 4, 6 and  
12–15 months
Alaskan Native  
adults (≥18 years)
Vaccine introduction: January 2001
VT carriage prevalence
1998–2000: 28.4%
2001: 17.7%
2002: 13.5%
2003: 5.8%
2004: 4.5%
P < 0.0001
3+PPV23 schedules
  Australia Mackenzie 
et al.10
Pre/postvaccine 
introduction 
observational 
study
PCV7 
(Wyeth)
2, 4, 6 and PPV23  
at 18 months
Aboriginal adults  
and older  
children in  
the Northern  
Territory
Vaccine introduction: late 2001
Percent of pneumococcal isolates that  
were VT
Among adults:
1996–1997 and 1999–2001: 25%
2002/4: 23.4%
Odds ratio (95%) 0.92 (0.45–1.90)
Among older children:
2000/1: 35.7% 2002/4: 21.1%
Odds ratio (95%) 0.48 (0.28–0.82)
TABLE 2. Continued
Loo et al The Pediatric Infectious Disease Journal • Volume 33, Number 1, Supplement 2, January 2014
S166  |  www.pidj.com  © 2013 Lippincott Williams & Wilkins
including 4 studies that specifically reported data on Vt-meningitis 
(table 3). All these studies were observational studies using either 
population-based surveillance or sentinel site data. no clinical trials 
of indirect effects among adults were identified in the published lit-
erature; we are aware of 1 such unpublished trial result that showed 
no effect in any age group (author data).46 Six studies provided data 
on a high-risk population, either indigenous (n = 4; 19.0%) or HIV-
infected (n = 2, 9.5%) persons. the definition of adult age group 
varied across studies; however, 4 (19.0%) reported data from the 
total population, including children <18 and adults ≥65 years of age.
many studies reporting indirect effects of pCV on Vt-IpD 
occurred in the setting of a 3+1 national immunization program 
(n = 12; 61.9%). Six studies (12.9%), conducted in the united 
Kingdom, Scotland, Italy, Denmark and norway, occurred in a 2+1 
setting. three studies, all conducted in Australia, used a 3+ppV23 
(among indigenous groups) and/or 3+0 (among nonindigenous 
groups) dosing schedule.23,26 no studies used a 2+0 schedule and 
no direct comparisons among dosing schedules were identified.
nearly all studies (n = 20; 95.2%) demonstrated a reduction 
in Vt-IpD among at least 1 adult age group, regardless of dosing 
schedule (2+1, 3+0, 3+ppV23 and 3+1). the degree of impact var-
ied by a specific age group, the outcome measured and the num-
ber of years post introduction (Fig. 2). Reductions in Vt-IpD were 
observed as early as 1 year after introduction. In general, reductions 
for all schedules were larger ≥3 years after introduction compared 
with reductions seen within 3 years of introduction (Fig. 3A, B).
Of the 12 studies, 9 (75.0%) using a 3+1 or 3+ppV23 
schedule took place in countries where catch-up campaigns were 
implemented during national introduction. Reductions in Vt-IpD 
among healthy adult groups in countries using 3+1 schedules 
ranged from 13% in Spain, 6 years after pCV introduction, to 92% 
in the united States, 7 years after introduction.11,25 Vaccine-type 
meningitis was reduced by 73% among the general population in 
Canada and by 67% among adults ages 18–39 years in the united 
States, both within 5 years after pCV introduction.12,19 One study 
conducted in the united States demonstrated a 67% reduction in 
Vt-IpD among Alaskan natives ages 18–44 years, also within 5 
years after introduction.
two studies identified in this review did not show a reduc-
tion in Vt-IpD among a reported adult group using a 3+1 schedule. 
TABLE 3. Summary of IPD Studies Evaluating Indirect Effects of 2 + 0, 2 + 1, 3 + 0, 3 + 1 and 3+PPV23 Schedules
Country Author Endpoints Evaluated
Indirect Groups 
Evaluated
Age Group 
(Years)
Number of 
 Baseline 
Years 
Reported
Baseline Value 
(per 100,000 
Unless 
 Otherwise 
Noted)
Maximum 
 Number of Years 
Reported After 
 Introduction
Percent  
Change in 
VT-IPD
2 + 1 schedule
  United Kingdom Miller et al.24 VT-IPD General 15–44 7 3.30 4 −88
45–64 7 7.70 4 −86
VT-meningitis General 5–64 7 0.10 4 −70
  United Kingdom Foster16 VT-IPD General ≥2 10 4.25 1 −22
  Norway Vestrheim et al.30 VT-IPD General 20–39 2 3.93 2 −22
40–64 2 12.19 2 −60
  Scotland Flasche et al.15 VT-IPD General 5–64 NS NS 3 −53R
  Denmark Lambertsen et al.22 VT-IPD General 5–65 NS 621 (CS) 2 −74
  Italy*† Del Grosso et al.14 VT-IPD General Gen Pop 3 227 (CS) 4 −15
3 + 0 schedule
  Australia Lehmann et al.23 VT-IPD General 15–29 8 1.85 2 −62
30–49 8 2.30 2 −43
50–64 8 4.35 2 −36
  Australia Roche et al.26 VT-IPD General 15–49 3 2.30 1 −35
50–64 3 5.10 1 −35
3+PPV23
  Australia Lehmann et al.23 VT-IPD Indigenous 15–29 5 4.7 6 6
30–49 5 15.80 6 −54
50–64 5 18.9 6 −43
  Australia Hanna et al.18 VT-IPD Indigenous ≥15 3 16.00 6 −75
3 + 1 schedule
  Canada Tyrrell et al.29 VT-IPD General Gen Pop 2 7.55 4 −67
  Canada Kellner et al.21 VT-IPD General 16–64 4 3.60 5 −39
  Canada Bettinger et al.12 VT-Meningitis General Gen Pop 2 75(CS) 5 −73
  United States Cohen et al.13 VT-IPD HIV+ 18–64 2 681(α) 7 −91
  United States Weatherholtz 
et al.31
VT-IPD Indigenous 18 to <40 6 5.50 6 −64
40 to <65 6 16.5 6 −58
  United States Singleton et al.28 VT-IPD General 18–44 6 4.10 5 −80
Indigenous 18–44 6 6.00 5 −67
  United States Moore et al.25 VT-IPD General 18–49 2 7.60 8 −92
  United States Jacobs et al.20 VT-IPD General Gen Pop 1 131 (CS) 7 −92
  United States Hsu et al.19 VT-meningitis General 18–39 2 0.30 5 −67
40–64 2 0.62 5 −61
  Spain*† Ardanuy et al.11 VT-IPD General 18–64 5 3.10 6 −13
VT-meningitis General Adults 5 0.37 6 25
  Spain*† Grau et al.17 VT-IPD HIV+ Adults 16 55 (CS) 6 −67
  Netherlands* Rodenburg et al.27 VT-IPD General 5–49 3 1.40 2 0
* Country did not have catch-up campaign.
† PCV was not part of national program; however, >50% coverage was reported.
CS, case series study; R, data were not available to calculate percent reduction; numbers here reflect those reported by the study; α, number given is the ratio of cases of IPD 
among HIV-infected persons per 100,000 persons 18–64 years of age living with AIDS; Genpop, general population; NS, not stated.
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FIGURE 2. Incidence of vaccine-type IPD among adults before and after PCV introduction, by dosing schedule.
FIGURE 3. A, Percent change in vaccine-type IPD ≤3 years of PCV introduction (n=13 studies). B, Percent change in vaccine-
type IPD >3 years of PCV introduction (n= 15 studies).
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In Spain, a 25% increase in Vt-meningitis was observed among 
all adults, which was accompanied by a 13% reduction in Vt-IpD 
among adults ages 18–64 years.11 Factors cited as possibly con-
tributing to this finding included a low pCV coverage (50% within 
6 years after introduction for high-risk groups) and an increase 
in in-migration to the area that could have impacted the indirect 
effects of vaccine introduction. In the netherlands, no change 
(0%) in Vt-IpD was observed among 5–49 year olds 2 years fol-
lowing introduction.27 Authors attributed the apparent absence of 
herd immunity despite high vaccine uptake among children (94%) 
to the lack of a catch-up campaign and short evaluation period.
We identified 2 studies reporting indirect effects of pCV on 
Vt-IpD among adults with HIV. Both studies took place in settings 
using a 3+1 schedule. In the united States, Cohen et al. reported 
a 91% reduction in the incidence of Vt-IpD among HIV-infected 
persons, from 681 per 100,000 persons 18–64 years of age living 
with AIDS in 1998/1999 to 64 per 100,000 persons in 2007. In 
Spain, Grau et al. reported a 67% reduction in Vt-IpD among 4011 
HIV-infected adults receiving care at a teaching hospital in Barce-
lona 6 years after vaccine introduction.
Of the 5 countries reporting data on the indirect effects 
of pCV on adult groups using a 2+1 schedule, all except Italy 
implemented some type of catch-up campaign among young 
children. Reported indirect effects on Vt-IpD with a 2+1 sched-
ule ranged from 15% among the general population in Italy to 
88% among 15–44 year olds in england and Wales.14,24 A 70% 
reduction in Vt-meningitis was also observed among adults 5–64 
years of age in england and Wales within 4 years after vaccine 
introduction.24
the 3 studies using either a 3+0 or a 3+ppV23 schedule all 
took place in Australia, where catch-up campaigns were conducted 
for both indigenous and nonindigenous children.23,26 these stud-
ies demonstrated similar reductions in Vt-IpD among indigenous 
(range 43–75%) and nonindigenous adults (range 35–62%) over 
15 years of age, although 1 study demonstrated a 6% increase in 
Vt-IpD among indigenous adults 15–29 years of age. In this study, 
TABLE 4. Summary of Syndromic Pneumonia Studies Evaluating Indirect Effects of 2 + 1, 3 + 0 and 3 + 1 Schedules
Country Reference Study  Design
Dosing  Schedule 
for PCV7 
(Wyeth)*
Endpoints 
 Evaluated
Indirect Groups 
 Evaluated (Years)
Detailed  
Findings Findings
2 + 1 schedules
  Poland Patrzalek et al.38 Sentinel 3, 5 and 
12 months
CXR  pneumonia, 
all-cause 
 hospitalizations
30–49
50–64
≥65
No evidence to prove that 
PCV7  introduction 
decreased incidence in 
age groups over 4 years; 
risk of pneumonia in 
unvaccinated remained 
unchanged
↔
3 + 0 schedules
  Australia Jardine et al.34 Population- 
based
2, 4 and  
6 months
Clinical 
 pneumonia, 
pneumococcal 
pneumonia
5–17
18–39
40–64
3–11% reduction  
(borderline significant) 
observed in age groups 
>4 years
↙
3 + 1 schedules
  Spain Ardunuy et al.11 Sentinel 2, 4, 6 and 
12–15 months
Pneumococcal 
pneumonia
Adults 39% increase ( significant), 
although 27% reduction 
in PCV7 types. 81% 
increase in non-PCV7 
types
↑
  Taiwan Lin et al.35 Passive,  
sentinel
3 + 1 Clinical 
 pneumonia, 
 all-cause 
 mortality
5–64
≥65
No significant reduction in 
5–64; significant reduc-
tion in 65+ (64.1%); 
however, greater use of 
PPV23
↙
  United States Grijalva et al.33 Sentinel 2, 4, 6 and 
12–15 months
Clinical 
 pneumonia, 
pneumococcal 
pneumonia, 
empyema
18–39 26% reduction in  
clinical pneumonia in 
18–39 years of age; rates 
declined in older groups 
but not significant
30% reduction in 
 pneumococcal 
 pneumonia
↓
  United States Nelson et al.37 Cohort study 2, 4, 6 and 
12–15 months
Clinical 
 pneumonia,  
CXR  pneumonia
18–49 living with 
children
No reductions seen; >18 
year age group had 
increased rates after 
PCV intro
↔
  United States Simonsen et al.39 Population- 
based
2, 4, 6 and 
12–15 months
Pneumococcal 
pneumonia
5–17
18–39
40–64
≥65
Significant reductions in 
all-cause  pneumonia 
 hospitalizations 
(5–17 and 18–39 years); 
90–95%  modeled  
reductions in 
 pneumococcal 
 pneumonia due to 
>18 year age group
↓
*No studies with other PCV product met inclusion criteria.
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other indigenous adults 30–49 and 50–64 years of age experienced 
reductions of 54% and 43%, respectively.23
Pneumonia
nine observational studies in this review evaluated the 
impact of pCV dosing schedules on clinical or radiologically 
confirmed pneumonia in older children or adults (table 4). most 
studies (n = 7, 78%) were conducted in europe, north America or 
Australia; the remaining 2 studies were from South Africa32 and 
taiwan.35 there were no studies that evaluated indirect pneumonia 
effects on high-risk populations. Additionally, no studies directly 
compared various dosing schedules on indirect populations and no 
RCts have evaluated the impact of pCV on pneumonia in unvac-
cinated populations.
Of the observational studies, 2 studies using 2+138 and 
3+034 schedules showed almost no impact on clinical or radio-
logically confirmed pneumonia (table 4). Of 5 studies using a 3+1 
schedule,11,33,35,37,39 3 showed any impact on pneumonia (table 4). the 
study conducted in taiwan35 found significant reductions in pneumonia 
only in adults ≥65 years of age, although the authors noted an increase 
in use of ppV23 among this population during the study period.
this analysis also found 2 case-control studies evaluating pCV 
impact on pneumonia in unvaccinated populations (table 5). One 
study, conducted in South Africa, evaluated the impact of a 3+0 sched-
ule on adults residing with children enrolled in an RCt for pCV9.32 
this study found no impact against pneumonia in adults during the 
clinical trial. the authors noted possible reasons for a lack of impact, 
including a large burden of HIV among adults in South Africa, tim-
ing of doses given in the infant schedule, the lack of a booster dose 
and <20% coverage in <5 year olds in the community during the trial. 
Another case-control study conducted in the united States after imple-
mentation of pCV7 into the national immunization program showed 
an 80% reduction in the odds of getting bacteremic pneumococcal 
pneumonia in adults that resided with a vaccinated child.36
DISCUSSION
Our review identified a substantial body of research evalu-
ating whether pCV use in young children leads to indirect effects 
in other age groups, although there are more data supporting some 
schedules than others. most of the data were from studies evaluat-
ing 2 or 3 primary dose schedules with a booster dose (2+1, 3+1 or 
3+ppV23), and among these, studies evaluating a 3+1 dosing sched-
ule were most common. While studies have evaluated pneumonia, 
Vt-np carriage and Vt-IpD, the demonstration of indirect effects 
was most consistent across studies and for all schedules for Vt-IpD.
Because the first countries to introduce pCV used a 3+1 
schedule, most of the available literature on indirect effects is for 
that schedule. the weight of evidence suggests that the use of a 3+1 
schedule as part of a routine vaccination program for all infants will 
result in reduction of carriage and disease in age groups not targeted 
to receive pCV. Of 12 studies that we identified evaluating the 3+1 
schedule for Vt-IpD, only 2 showed no evidence of reductions in 
Vt-IpD in unimmunized age groups; both took place in countries 
without catch-up campaigns and vaccine coverage in the population 
may have been insufficient to demonstrate indirect effects.11,27 Vt-np 
carriage studies have also shown indirect effects with 3+1 schedules. 
the impact on Vt-np carriage was observed in high-risk popula-
tions; no np carriage studies with indirect effects were conducted in 
general populations. Studies of syndromic pneumonia only showed 
an impact with 3+1 schedules. Among 6 studies evaluating the 3+1 
schedule, only 2, from Spain11 and the united States,37 observed 
increases in overall trends of pneumonia (pneumococcal, clinical and 
radiologically confirmed), with authors of both studies speculating 
that the overall increases were due to increases in nonvaccine sero-
type disease, although other secular trends could have contributed.
A smaller but growing number of studies have examined 
3-dose (2+1 and 3+0) schedules. most policy makers recently adopt-
ing pCV have used 1 of these schedules and the World Health Organ-
ization recently updated their recommendation for pCV to be used on 
either of these 3-dose schedules.47 Our review did not find sufficient 
data to directly compare these 2 schedules or to make conclusions 
regarding the impact of these schedules on Vt-np carriage or syn-
dromic pneumonia; statistically significant indirect effects for pneu-
monia and Vt-np carriage using 2+1 and 3+0 schedules were not 
observed in any of the 6 studies of these outcomes identified by our 
review, although many of these studies were conducted early in the 
immunization programs or evaluated nonspecific endpoints. Despite 
these limitations, both 3-dose schedules appear to have indirect 
effects on Vt-IpD when introduced nationally. Substantial reductions 
in Vt-IpD were observed among young adult groups in 5 european 
countries using a 2+1 national immunization schedule.14–16,22,24,30 In 
countries with catch-up campaigns, this reduction was observed as 
early as 1 year after vaccine introduction. two studies evaluated 3+0 
schedules for indirect effects on Vt-IpD and both found significant 
reductions. One 3+0 study in Australia did find 3–11% reductions 
in pneumonia; however, these findings were only borderline sig-
nificant.34 Additionally, a 3+ppV23 schedule in Australia showed 
a decrease in Vt-np carriage among older children but not among 
adults.10 However, other studies suggest that ppV23 boosters do not 
affect Vt-carriage,48 and thus a 3+ppV23 schedule likely approxi-
mates a 3+0 schedule in terms of benefits against Vt-carriage.
this review also found studies of indirect effects of pCV on 
high-risk populations, including 9 studies evaluating pCV on either 
Vt-np carriage9,10,42,43 or Vt-IpD13,17,18,23,28,31; no studies evaluated 
pneumonia and all used 3+1 or 3+ppV23 schedules. Seven studies 
focused on the impact of pCV on indigenous populations, includ-
ing Australian Indigenous, Alaskan native and American Indian 
TABLE 5. Summary of Syndromic Pneumonia Case–Control Studies Evaluating Indirect Effects of 3 + 0 and 3 + 1 
Schedules
Case-control studies
Country Reference Study Design Vaccine Product ( Manufacturer)
Dosing Schedule 
for PCV
n of 
 Population Population Endpoint
Odds Ratio  
(95% CI)
South Africa Albrich et al.32 Substudy of 
PCV9  clinical 
trial
PCV9 (Wyeth) 6, 10 and 14 
weeks
255 Adults All cause 
 pneumonia
1.07 (0.79–1.45) 
(Crude)
Pneumococcal 
pneumonia
1.00 (0.39–2.59) 
(Crude)
United States Metlay et al.36 Risk factor 
analysis
PCV7 (Wyeth) 2, 4, 6, 12–15 
months
842 Adults Bacteremic 
pneumococcal 
pneumonia
0.2 (0.1–0.8) 
(Adjusted)
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populations, and 2 focused on HIV-infected populations. Despite 
these varying populations, the findings were consistent. All studies 
noted reductions in disease in older children and adults, suggesting 
indirect impact of pCV on high-risk populations. these observa-
tions may be of relevance to countries with a high burden of HIV 
or vulnerable populations at higher risk of pneumococcal disease.
While the strength of this analysis is the diversity of settings 
and study designs included, both for high-risk and nonhigh-risk 
populations, there are some limitations to our analysis. the het-
erogeneity of the data did not allow for direct comparisons among 
schedules and since many factors contribute to the indirect impact 
of a vaccine schedule, this analysis was unable to fully address the 
wide variability in study settings and factors that may contribute to 
the relative impact of pCV schedules (eg, vaccine coverage, pres-
ence of a catch up campaign, proportion of the population under 5 
years of age, HIV prevalence). Additionally, few data points exist 
for most of the outcomes we evaluated. Only 1 study directly com-
pared impact among dosing schedules; this Vt-np study from the 
netherlands showed no impact of either a 2+0 or a 2+1 schedule on 
np carriage in older siblings and parents of vaccinated and unvac-
cinated children participating in an individual RCt. this study was 
the only study to evaluate a 2+0 schedule.44,45 Furthermore, some 
of the studies presented here were small and/or were substudies of 
clinical trials and therefore may not accurately represent the herd 
protection of vaccine introduction in a broad population. many 
of the studies took place over relatively short periods; since full 
realization of herd effects in a population may take years,1 study 
periods of just a few years likely underestimate the measured 
herd effects in some studies. As pCV introductions in lower- and 
middle-income countries have only recently occurred,49 almost all 
data on impact from routine use came from high-income, early 
introducing countries with more mature immunization programs, 
which may be more likely to show indirect effects; however, a 
number of studies are ongoing and data will likely be available 
soon on the impact of routine use of pCV on unvaccinated older 
children and adults in lower- and middle-income settings.
the findings of our review suggest to policy makers that, 
should they adopt either a 3- or 4-dose pCV schedule, indirect 
effects are likely to add to the overall benefits seen from their pro-
gram. the evidence to date is strong for the 3+1 schedule and is 
growing for the 3-dose schedules (2+1 and 3+0). more data to sup-
port evidence of herd effects from countries using either the 2+1 
or 3+0 schedule would be useful, in particular for the outcomes of 
Vt-np carriage and pneumonia, from developing country settings 
where transmission may be more intense and across a wider age 
range than in high-income populations and for the new generation of 
conjugate vaccines (pCV10 and pCV13). Because studies of pCV 
effect on np carriage in vaccinated children show that 3- and 4-dose 
schedules reduce colonization,4 we anticipate that with time and 
more study, vaccination of infants using all of these schedules will 
be found to prevent a variety of disease syndromes and coloniza-
tion in unvaccinated age groups. For policy makers trying to deter-
mine the best schedule to adopt for their national pCV program, 
the evidence summarized here on indirect effects should provide an 
adjunct to data on the direct benefits of various pCV schedules for 
infants and to programmatic and epidemiologic factors specific to 
their situation that would drive their decisions on pCV use.
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